2023-03-23 00:42:02 ET
Summary
- Calumet reported earnings much negatively affected by weather-caused shutdowns in December.
- A rationalization of the results strongly supports that the company is still on a lucrative path.
- MRL, the RND business, begin selling product in the latter part of December.
- A pre-treating unit op is now in startup, after which, the company has contracted product to generate $250 million in EBITDA on a yearly bias.
- Margins for specialty remain strong, supporting strong cash generation from its older businesses.
For further details see:
Calumet Specialty's Flexible And Lucrative Vision Opens A Barn Sized Investment Door